Consensus Control Strategy for the Treatment of Tumour with Neuroadaptive Cellular Immunotherapy

This paper presents a novel neuro-adaptive cellular immunotherapy control strategy that leverages the high efficiency and applicability of chimeric antigen receptor-engineered T (CAR-T) cells in treating cancer. The proposed real-time control strategy aims to maximize tumor regression while ensuring the safety of the treatment. A dynamic growth model of cancer cells under the influence of cellular immunotherapy is established for the first time, which aligns with clinical experimental results. Utilizing the backstepping method, a novel consensus reference model is designed to consider the characteristics of cancer cell changes during the treatment process and conform to clinical rules. The model is segmented and continuous, with cancer cells expected to decrease in a step-like manner. Furthermore, a prescribed performance mechanism is constructed to maintain the therapeutic effect of the proposed scheme while ensuring the transient performance of the system. Through the analysis of Lyapunov stability, all signals within the closed-loop system are proven to be semiglobally uniformly ultimately bounded (SGUUB). Simulation results demonstrate the effectiveness of the proposed control strategy, highlighting its potential for clinical application in cancer treatment.